- Conditions
- COVID-19
- Interventions
- BRII-196, BRII-198, Placebo, Remdesivir
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 353 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 76
- States / cities
- Tucson, Arizona • Fresno, California • Loma Linda, California + 52 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pneumonia, Idiopathic Pneumonia Syndrome
- Interventions
- Etanercept, Placebo plus corticosteroid
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 12
- States / cities
- Gainesville, Florida • Indianapolis, Indiana • Baltimore, Maryland + 9 more
- Conditions
- Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
- Interventions
- Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment
- Other · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Biological Availability, Healthy Participants
- Interventions
- Nirmatrelvir/ ritonavir
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Fluconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 3
- States / cities
- Oakland, California • New York, New York • Philadelphia, Pennsylvania
- Conditions
- Healthy Participants
- Interventions
- S-892216-LAI, Placebo
- Drug
- Lead sponsor
- Shionogi
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 98 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 2
- States / cities
- Lenexa, Kansas • Salt Lake City, Utah
- Conditions
- Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
- Interventions
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Other
- Lead sponsor
- University of Calgary
- Other
- Eligibility
- 9 Months to 21 Years
- Enrollment
- 1,040 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 19 more
- Conditions
- Necrotizing Soft Tissue Infection, Sepsis
- Interventions
- HAT, Placebo
- Drug
- Lead sponsor
- Ascension Health
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Wichita, Kansas
- Conditions
- Asymptomatic Condition, Infection Viral, Coronavirus Infections, Severe Acute Respiratory Syndrome Coronavirus 2, Coronaviridae Infections, RNA Virus Infections, Virus Diseases, Communicable Disease
- Interventions
- To assess for development of IgG antibodies against SARS-CoV2
- Diagnostic Test
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6,313 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Long COVID
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Scripps Translational Science Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Colorectal Cancer, Head and Neck Cancer, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic/Myeloproliferative Diseases, Prostate Cancer, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- doxorubicin hydrochloride, motexafin gadolinium
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Madison, Wisconsin
- Conditions
- B-cell Acute Lymphoblastic Leukemia
- Interventions
- CD19x22 CAR T
- Biological
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 3 Months to 30 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Complicated Urinary Tract Infection Including Acute Pyelonephritis
- Interventions
- Combination of Imipenem/Cilastatin and XNW4107, Meropenem
- Drug
- Lead sponsor
- Evopoint Biosciences Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 780 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- 3'-deoxy-3'-[18F]fluorothymidine
- Device
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
- Interventions
- Fludarabine, Cyclophosphamide, Mesna, CD19-CD22 CAR T cell infusion
- Drug · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Covid-19
- Interventions
- Quidel Sofia SARS Antigen FIA
- Diagnostic Test
- Lead sponsor
- Carilion Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 117 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Roanoke, Virginia
- Conditions
- Acute Otitis Media, Ear Infection, Pediatric Infectious Disease
- Interventions
- Changes to the electronic health record (EHR), Individualized audit and feedback reporting for clinicians, Clinician education sessions, Use of a shared decision-making (SDM) aide, Shared decision-making (SDM) education
- Other
- Lead sponsor
- Intermountain Health Care, Inc.
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 1,566 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Chicago, Illinois • Murray, Utah
- Conditions
- Acute Respiratory Distress Syndrome, Sepsis
- Interventions
- Inhaled Carbon Monoxide at CFK equation-determined personalized dose (200-500 ppm to achieve a COHb level of 6-8%), Inhaled Medical air
- Drug · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • St Louis, Missouri • Brooklyn, New York + 2 more
- Conditions
- Urinary Tract Infections
- Interventions
- LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX
- Drug
- Lead sponsor
- Locus Biosciences
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 318 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 17
- States / cities
- Fresno, California • Lancaster, California • Los Angeles, California + 13 more
- Conditions
- Skin and Subcutaneous Tissue Bacterial Infections, Skin Structures and Soft Tissue Infections
- Interventions
- delafloxacin, vancomycin, aztreonam
- Drug
- Lead sponsor
- Melinta Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 850 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Montgomery, Alabama • Anaheim, California + 28 more
- Conditions
- Cancer
- Interventions
- aprepitant, dexamethasone, ondansetron, placebo
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Acute Respiratory Failure, Encephalopathy, ARDS, Sepsis, Critical Illness
- Interventions
- Exersides
- Device
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- San Diego, California • Baltimore, Maryland • Burlington, Vermont
- Conditions
- Recurrent Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hairy Cell Leukemia, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent T Acute Lymphoblastic Leukemia, Refractory Acute Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Hairy Cell Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis
- Interventions
- Acetaminophen, Dexamethasone, Diphenhydramine, Flotetuzumab, Ibuprofen, Ranitidine
- Drug · Biological
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Infectious Gastroenteritis
- Interventions
- FilmArray™ Gastrointestinal (GI) Panel
- Device
- Lead sponsor
- BioFire Diagnostics, LLC
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 1,545 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Kansas City, Missouri • Columbus, Ohio + 2 more